Table: Anges -Q1 group results
May 8 (Reuters)-
Anges, Inc.
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
3 months ended 3 months ended Year to
Mar 31, 2026 Mar 31, 2025 Dec 31, 2026
LATEST YEAR-AGO LATEST
RESULTS RESULTS FORECAST
Sales 203 mln 169 mln 1.33
(+20.4 pct) (+49.0 pct) (+52.2 pct)
Operating loss 1.50 loss 1.26 loss 10.23
Recurring loss 1.11 loss 1.24 loss 10.24
Net loss 1.08 loss 1.25 loss 10.25
EPS loss 2.74 yen loss 3.99 yen loss 25.88 yen
Ann Div NIL NIL
-Q2 div NIL NIL
-Q4 div NIL NIL
NOTE - Anges, Inc..
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4563.T
Recent news on AnGes
See all newsTable: Anges -Q1 group results
Brief: Vasomune Therapeutics, Inc., And Anges, Inc., Announce Us FDA Clearance Of Investigational New Drug (Ind) Application For Pegevongitide (Av-001) Treatment In Resuscitation Of Severely Burned Patients
Table: Anges -2025 parent results
Table: Anges -2025 group results
Brief: Anges & Vasomune Therapeutics Enter Agreement For AV-001